Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. E3 Breast Cancer Study- evaluating everolimus with endocrine therapy
Cancer - Breast,
Grace Makari-Judson, MD
D’Amour Center for Cancer Care
3350 Main Street, Springfield MA 01199
The purpose of this study is to see whether treatment with everolimus plus hormone treatment after chemotherapy will increase the time without your cancer returning. The current standard treatment after chemotherapy is hormone treatment alone. The combination of hormone-treatment and everolimus is experimental in patients with breast cancer.
Invasive non-metastatic breast cancer; ER/PR positive; HER2 negative
Rae Lynn Defeo